Anxo Pharmaceutical Co., Ltd. (TPEX:6677)
Taiwan · Delayed Price · Currency is TWD 16.85
-0.45 (-2.60%)
Sep 8, 2026, 1:08 PM CST
Anxo Pharmaceutical Financials Overview
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 878.88 | 843.26 | 895.32 | 939.94 | 866.27 | 824.1 |
Revenue Growth | 4.22% | -5.81% | -4.75% | 8.50% | 5.12% | -4.85% |
Gross Profit Gross Profit Growth | 323.15 | 300.18 | 325.48 | 396.93 | 331.46 | 331.66 |
Operating Income Operating Income Growth | -25.65 | -43.69 | -56.57 | 53.31 | 5.95 | 40.1 |
Net Income Net Income Growth | -20.46 | -34.13 | -57.21 | 21.86 | -12.56 | 19.23 |
Earnings Per Share EPS Growth | -0.37 | -0.61 | -1.03 | 0.42 | -0.26 | 0.40 |
EPS Growth | - | - | - | - | - | -38.56% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Development of Western Medicine and Marketing Department Development of Western Medicine and Marketing Department Growth | 848.55 | 826.42 | 788.71 | 784.93 | 721.91 | 726.66 |
Western Medicine Manufacturing Department Western Medicine Manufacturing Department Growth | 401.16 | 408.03 | 485.87 | 533.31 | 491.47 | 426.28 |
Adjustment and Write-Off Adjustment and Write-Off Growth | -370.83 | -391.19 | -379.27 | -378.3 | -347.11 | -328.83 |
Total Total Growth | 878.88 | 843.26 | 895.32 | 939.94 | 866.27 | 824.1 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 323.91 | 363.37 | 361.14 | 385.18 | 241.32 | 214.18 |
Total Debt Total Debt Growth | 741.46 | 734.97 | 726.63 | 787.84 | 887.09 | 882.47 |
Net Cash (Debt) Net Cash Growth | -417.55 | -371.6 | -365.49 | -402.66 | -645.76 | -668.29 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -7.46 | -6.65 | -6.56 | -7.81 | -13.41 | -13.78 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 55.59 | 55.34 | 111.97 | -2.66 | 71.27 | 78.35 |
Capital Expenditures CapEx Growth | -79.97 | -47.74 | -42.34 | -57.83 | -14.59 | -34.85 |
Free Cash Flow Free Cash Flow Growth | -24.38 | 7.6 | 69.63 | -60.48 | 56.68 | 43.51 |
Free Cash Flow Growth | - | -89.09% | - | - | 30.27% | -0.90% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 36.77% | 35.60% | 36.35% | 42.23% | 38.26% | 40.24% |
Operating Margin | -2.92% | -5.18% | -6.32% | 5.67% | 0.69% | 4.87% |
Pretax Margin | -3.22% | -5.41% | -6.70% | 4.12% | -0.54% | 2.95% |
Profit Margin | -2.33% | -4.05% | -6.39% | 2.33% | -1.45% | 2.33% |
FCF Margin | -2.77% | 0.90% | 7.78% | -6.44% | 6.54% | 5.28% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Period Ending | Sep '26 Sep 8, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Dividend Per Share Dividend Per Share Growth | 0.399 | - | - | 0.400 |
Dividend Per Share Growth | - | - | - | - |
Dividend Yield | 2.38% | - | - | 0.83% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 8, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | 123.88 | - | 61.60 |
P/FCF Ratio | - | 137.86 | 19.18 | - | 25.16 | 27.23 |
PS Ratio | 0.85 | 1.24 | 1.49 | 2.88 | 1.65 | 1.44 |